Answers are grounded in this paper and cite their sources.
Our data do not provide support for the addition of a single pulsed dose of intravenous methylprednisolone to conventional intravenous immune globulin therapy for the routine primary treatment of children with Kawasaki disease. (ClinicalTrials.gov number, NCT00132080 [ClinicalTrials.gov].)
No takes yet. Share an insight, caveat, or question.
Newburger et al. (2007) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: